Securities Investigation- Aeolus Pharmaceuticals
Are you concerned about your investment in Aeolus Pharmaceuticals? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Arbitration claim against the brokerage firm that sold you the investment.
Aeolus Pharmaceuticals, based in Mission Viejo, CA, has been engaged in the development of medical countermeasures for radiological, chemical and biological threats under programs previously supported by funding from the United States government.
According to a press announcement March 23, 2018, the company has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to enter into a General Assignment agreement with John D. McLaughlin, Jr., Esq. as the Assignee of all of Aeolus’ remaining assets.
Aeolus has reportedly transferred its assets to McLaughlin to liquidate these assets and distribute any proceeds to creditors. If the recovered value of these assets is not greater than the liabilities of Aeolus, there will not be any residual value for stockholders. In connection with the Assignment, Aeolus will discontinue the development of its compounds and all other operations, according to the statement.
Investigating Potential Claims
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for unsuitably recommending high risk investments, like Aeolus Pharmaceuticals to investors.
Brokerage firms are required to perform due diligence on any offering they recommend and to ensure that all recommendations made are suitable in light of the client’s age, investment experience, net worth, income, and investment objectives.
If a firm fails to perform due diligence or makes an unsuitable recommendation, the broker-dealer can be held responsible for any losses in a FINRA arbitration claim.
FINRA can help resolve problems and disputes through two non-judicial proceedings: arbitration and mediation. FINRA’s Dispute Resolution forum handles nearly all of the securities-related arbitrations and mediations in the United States.
If you have concerns regarding your investment in Aeolus Pharmaceuticals and would like to speak with a securities attorney about your options, please call The White Law Group at 888-637-5510.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.
For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visithttps://whitesecuritieslaw.com.
Tags: Aeolus Pharmaceuticals complaints, Aeolus Pharmaceuticals default, Aeolus Pharmaceuticals help, Aeolus Pharmaceuticals high commissions, Aeolus Pharmaceuticals information, Aeolus Pharmaceuticals investigation, Aeolus Pharmaceuticals investment, Aeolus Pharmaceuticals investment losses, Aeolus Pharmaceuticals investor relations, Aeolus Pharmaceuticals investors, Aeolus Pharmaceuticals Laidlaw, Aeolus Pharmaceuticals losses, Aeolus Pharmaceuticals ppm, Aeolus Pharmaceuticals private placement, Aeolus Pharmaceuticals prospectus, Aeolus Pharmaceuticals recovery options, Aeolus Pharmaceuticals risk, Aeolus Pharmaceuticals stock information, Aeolus Pharmaceuticals update, Aeolus Pharmaceuticals liquidation Last modified: December 3, 2018